Related Experiment Videos
Therapy of hepatitis C: overview
1Department of Medicine, University of Southern California, Los Angeles 90033-4581, USA.
Hepatology (Baltimore, Md.)
|September 26, 1997
Summary
Alpha interferon therapy offers transient responses in up to 40% of chronic hepatitis C patients. Longer treatment durations and combination therapies show promise for sustained improvement, but predicting response remains challenging.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Chronic hepatitis C (HCV) affects millions globally, necessitating effective antiviral treatments.
- Alpha interferon has been a cornerstone therapy, with research focusing on optimizing its use.
- Understanding patient response and treatment durability is crucial for managing HCV.
Framework:
- Four alpha interferon variants (alfa-2b, alfa-2a, alfa-n1, CIFN) evaluated for chronic hepatitis C.
- Response assessment uses biochemical (ALT) and virological (HCV RNA PCR) endpoints.
- Treatment outcomes defined as end-of-treatment response (ETR) and sustained response (SR).
Implementation:
- Biochemical ETR rates range from 35-50% after 6 months of therapy.
- Sustained response (SR) rates after 6 months are 8-21%, with higher rates for 12-month regimens.
- Long-term follow-up reveals sustained clinical, virological, and histological benefits in SR patients.
Implications:
- Baseline factors are insufficient for predicting sustained response to interferon.
- Therapeutic trials are recommended to determine optimal treatment strategies.
- Further research is needed for better virological endpoints, side effect management, and understanding interferon resistance.
- Novel regimens including induction and combination therapies (e.g., with ribavirin) are critical for future HCV treatment development.